Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE009 (AUS) (Dr. Novak)
· consented 2022-03-13
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-22 (study day 187); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 204); relationship: not assessed; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2022-12-11 (study day 267); relationship: N
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 451); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 585); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.